Worth Peripherals Approves Q1 FY27 Results, Subsidiary Loan & Equity Infusion
Worth Peripherals approved Q1 FY27 unaudited results. Its subsidiary, Worth Wellness, commenced commercial production. The company infused ₹30 crore equity and approved a ₹20 crore loan to its subsidiary. M/s. RS Mantri And Associates appointed as Secretarial Auditor for 5 years.
The commencement of commercial production by a subsidiary, significant equity infusion and loan to the subsidiary, and approval of financial results are material events that can have a substantial impact on the company's operations and financial performance.
The announcement includes positive developments such as the commencement of commercial production by a subsidiary, approval of financial results, and strategic financial decisions like equity infusion and loan disbursement to the subsidiary.
Worth Peripherals Limited announced the outcome of its Board Meeting held on August 4, 2026. The Board approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026, along with the Limited Review Report.
Additionally, the company approved the appointment of M/s. RS Mantri And Associates as Secretarial Auditor for a term of five years, commencing from the conclusion of the upcoming Annual General Meeting until the conclusion of the 35th AGM in 2031, subject to shareholders' approval.
Key updates were also provided regarding its wholly-owned subsidiary, Worth Wellness Private Limited. The subsidiary has successfully commenced commercial production at its new corrugated packaging manufacturing facility in Indore, Madhya Pradesh, effective August 1, 2026. This facility is equipped with advanced technology and automation, enhancing the company's manufacturing capabilities and operational efficiency. The subsidiary also plans to install a solar power plant at the new facility.
Furthermore, the Board approved the allotment of 60,00,000 equity shares of face value ₹10 each at an issue price of ₹50 per share to the holding company, Worth Peripherals Limited, aggregating to ₹30 crore. This conversion of an outstanding loan into equity shares was approved by the subsidiary's board on August 4, 2026.
The company also approved an inter-corporate loan of ₹20 crore to Worth Wellness Private Limited for its funding requirements. The loan agreement, to be executed on August 7, 2026 (subject to shareholder approval), will be for a period of three years at prevailing RBI yield rates, with an option for Worth Peripherals to convert the loan into equity.
The Board Meeting commenced at 11:00 AM and concluded at 02:30 PM. The company will separately inform about the AGM date and record date for final dividend and e-voting.
What to do with a filing like this
Worth Peripherals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Worth Peripherals Limited. Read the original for the full detail.